PURPOSE: Previously, aliphatic β-nitroalcohols (BNAs) have been studied as a means to chemically induce tissue cross-linking (TXL) of cornea and sclera. There are a number of related and possibly more potent agents, known as formaldehyde releasers (FARs), that are in commercial use as preservatives in cosmetics and other personal care products. The present study was undertaken in order to screen such compounds for potential clinical utility as therapeutic TXL agents. METHODS: A chemical registry of 62 FARs was created from a literature review and included characteristics relevant to TXL such as molecular weight, carcinogenicity/mutagenicity, toxicity, hydrophobicity, and commercial availability. From this registry, five compounds [diazolidinyl urea (DAU), imidazolidinyl urea (IMU), sodium hydroxymethylglycinate (SMG), DMDM hydantoin (DMDM), 5-Ethyl-3,7-dioxa-1-azabicyclo [3.3.0] octane (OCT)] were selected for efficacy screening using two independent systems, an ex vivo rabbit corneal cross-linking simulation setup and incubation of cut scleral tissue pieces. Treatments were conducted at pH 7.4 or 8.5 for 30 minutes. Efficacy was evaluated using thermal denaturation temperature (Tm), and cell toxicity was studied using the trypan blue exclusion method. RESULTS: Cross-linking effects in the five selected FARs were pH and concentration dependent. Overall, the Tm shifts were in agreement with both cornea and sclera. By comparison with BNAs previously reported upon, the FARs identified in this study were significantly more potent but with similar or better cytotoxicity. CONCLUSIONS: The FARs, a class of compounds well known to the cosmetic industry, may have utility as therapeutic TXL agents. The compounds studied thus far show promise and will be further tested. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: Previously, aliphatic β-nitroalcohols (BNAs) have been studied as a means to chemically induce tissue cross-linking (TXL) of cornea and sclera. There are a number of related and possibly more potent agents, known as formaldehyde releasers (FARs), that are in commercial use as preservatives in cosmetics and other personal care products. The present study was undertaken in order to screen such compounds for potential clinical utility as therapeutic TXL agents. METHODS: A chemical registry of 62 FARs was created from a literature review and included characteristics relevant to TXL such as molecular weight, carcinogenicity/mutagenicity, toxicity, hydrophobicity, and commercial availability. From this registry, five compounds [diazolidinyl urea (DAU), imidazolidinyl urea (IMU), sodium hydroxymethylglycinate (SMG), DMDM hydantoin (DMDM), 5-Ethyl-3,7-dioxa-1-azabicyclo [3.3.0] octane (OCT)] were selected for efficacy screening using two independent systems, an ex vivo rabbit corneal cross-linking simulation setup and incubation of cut scleral tissue pieces. Treatments were conducted at pH 7.4 or 8.5 for 30 minutes. Efficacy was evaluated using thermal denaturation temperature (Tm), and cell toxicity was studied using the trypan blue exclusion method. RESULTS: Cross-linking effects in the five selected FARs were pH and concentration dependent. Overall, the Tm shifts were in agreement with both cornea and sclera. By comparison with BNAs previously reported upon, the FARs identified in this study were significantly more potent but with similar or better cytotoxicity. CONCLUSIONS: The FARs, a class of compounds well known to the cosmetic industry, may have utility as therapeutic TXL agents. The compounds studied thus far show promise and will be further tested. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
Authors: MiJung Kim; Anna Takaoka; Quan V Hoang; Stephen L Trokel; David C Paik Journal: Invest Ophthalmol Vis Sci Date: 2014-04-10 Impact factor: 4.799
Authors: David C Paik; Quan Wen; Richard E Braunstein; Suzanna Airiani; Stephen L Trokel Journal: Invest Ophthalmol Vis Sci Date: 2008-10-03 Impact factor: 4.799
Authors: Quan V Hoang; Quan Wen; David C Paik; Yong Yao Chun; Ronald Silverman; Takayuki Nagasaki; Stephen L Trokel; Mariya Zyablitskaya Journal: Br J Ophthalmol Date: 2021-10-20 Impact factor: 5.908
Authors: Su-Young Kim; Natasha Babar; Emilia Laura Munteanu; Anna Takaoka; Mariya Zyablitskaya; Takayuki Nagasaki; Stephen L Trokel; David C Paik Journal: Cornea Date: 2016-04 Impact factor: 2.651
Authors: Anna Takaoka; Natasha Babar; Julia Hogan; MiJung Kim; Marianne O Price; Francis W Price; Stephen L Trokel; David C Paik Journal: Invest Ophthalmol Vis Sci Date: 2016-01-01 Impact factor: 4.799
Authors: Mariya Zyablitskaya; Anna Takaoka; Emilia L Munteanu; Takayuki Nagasaki; Stephen L Trokel; David C Paik Journal: Invest Ophthalmol Vis Sci Date: 2017-01-01 Impact factor: 4.799
Authors: Patrick B Rapuano; Alexandra H Scanameo; Daeryl E Amponin; Sefy A Paulose; Mariya Zyablitskaya; Anna Takaoka; Leejee H Suh; Takayuki Nagasaki; Stephen L Trokel; David C Paik Journal: Invest Ophthalmol Vis Sci Date: 2018-01-01 Impact factor: 4.799